Studies of the Economics of Cancer Prevention, Screening, and Care (R21)

The summary for the Studies of the Economics of Cancer Prevention, Screening, and Care (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Studies of the Economics of Cancer Prevention, Screening, and Care (R21): It is estimated that the economic burden of cancer in the United States in 2002 was equivalent to $172 billion, including $61 billion in direct medical expenditures. As cancer survival improves and as the U.S. population ages, it is likely that the economic aspects of cancer will loom larger in policy discussions. Over the coming decades the U.S. health care system, including public sector programs such as Medicare and Medicaid, will face the challenge of covering an increasing array of health care procedures and services with fiscal resources that are limited by global budget constraints. Under these circumstances, there will be increased need for understanding how economic resources are used across the cancer continuum, from prevention through end-of-life care, and in the context of different organizational settings, for careful economic evaluation of conventional and innovative cancer control interventions and for a better understanding of how economic factors influence the welfare of cancer patients, and decision process about the use of cancer prevention, screening and treatment interventions. These are the types of issues addressed by this Program Announcement (also called Funding Opportunity Announcement). The Division of Cancer Control and Population Sciences (DCCPS) of the National Cancer Institute (NCI), and the Agency for Health Care Research and Quality (AHRQ), invite investigator-initiated grant applications for research directed at increasing the knowledge base in the area of the economic aspects of cancer prevention, screening, and care. The goal of this program announcement is to generate new economic knowledge that will promote the optimal design of cancer prevention and control trial studies and interventions and will facilitate the formulation of effective health care policy related to cancer prevention and control. NCI has an interest in economic and health services studies with particular emphasis on meeting the goals of the NCI Quality of Cancer Care Initiative (see http://plan.cancer.gov). This Funding Opportunity Announcement (FOA) also relates to the general health services and outcomes and effectiveness research supported by the AHRQ for a wide range of clinical conditions, including cancer. The overall goal of this Initiative is to enhance the state-of-the-science on the quality of cancer care and inform federal decision making on care delivery, coverage, and regulation. This initiative requests research applications on new methods development, the synthesis and extension of existing methods, and innovative data gathering strategies. Applications that propose to implement actual data collection on a pilot or full-scale basis as well as analytical studies that use existing data and methodology may also be submitted.-Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications; therefore, the anticipated number of awards is not known. -This FOA utilizes the Exploratory/Developmental grant (R21) mechanism and runs in parallel with an FOA of identical scientific scope, PA-04-017, that solicits applications under the NIH Research Project Grant (R01) award mechanism. -Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. -The total project period for an application submitted in response to this funding opportunity may not exceed 2 years. Direct costs are limited to $275,000 over an R21 2-year period, with no more than $200,000 in direct costs allowed in any single year. -Eligible organizations include: for-profit organizations; non-profit organizations; public or private institutions, such as universities, colleges, hospitals and laboratories; units of State governments; units of State Tribal governments; units of local governments; units of local Tribal governments; eligible institutions of the Federal government; domestic institutions; foreign institutions; and faith-based or community-based organizations. -Eligible Project Directors/Principal Investigators (PDs/PIs): any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. -Applicants may submit more than one application, provided each application is scientifically distinct.